share_log

IX Biopharma Widens Net Loss by 12% in FY2024

Singapore Business Review ·  Aug 27 16:51

Loss per share stood at $0.0141.

iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.

Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.

Loss per share stood at $0.0141 from $0.0126 a year ago.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment